Eusa acquires Asparec development rights from Alizé Pharma
Eusa Pharma has acquired the exclusive worldwide development and commercialisation rights to Asparec for the treatment of acute lymphoblastic leukemia (ALL) from Alizé Pharma.
Asparec is a recombinant, pegylated Erwinia chrysanthemi-derived asparaginase, and is currently in Phase I development for the treatment of ALL patients with hypersensitivity to standard-of-care.
As per the agreement, Eusa will pay Alizé Pharma an upfront fee, regulatory milestone payments and royalties on future product sales.
Preclinical data suggested that Asparec is potentially long acting and less immunogenic than currently available asparaginase Erwinia chrysanthemi.
Eusa Pharma president and CEO Bryan Morton said the deal follows the approval of company's first internally developed product, and further underlines its strategic transition into a fully fledged development as well as commercialization organization.
Alizé Pharma president and founder Thierry Abribat said the agreement validates the company's medical approach and emphasizes its drug development capabilities.
Related Insight
Suppliers Directory
GC-2 - Central Laboratory Solutions for Pharmaceutical Research and Development
Precise, continually updated information is an essential element of the efficiency of the best products and services.
Suppliers
Sheffield Bio-Science - Cell Nutrition and Excipient Market Solutions
Sheffield Bio-Science is a leader that demonstrates excellence in delivering consistent, high yielding, customer- specific solutions for the cell nutrition and excipient markets.
Suppliers
PolyPeptide Group - Proprietary and Generic GMP-Grade Peptides
The PolyPeptide Group is a privately-held group of manufacturing companies that focuses on proprietary and generic GMP-grade peptides for the pharmaceutical, cosmetic and biotechnological market.
Suppliers
EXTEDO - Key Services and Solutions Provider in eRegulatory Affairs
EXTEDO is the key solutions and services provider in the field of eRegulatory Affairs.
Suppliers
Production & Manufacturing
Fine & Speciality Chemicals
Manufacturing
Process & Production
OTC
Drug Research Drug Delivery Drug Discovery & Development
Contract Research & Services Clinical Trials Contract Research Contract Services
Automation IT & Software Laboratory Instrumentation
Inward Investment Packaging Regulatory Affairs
Drug Research Drug Delivery Drug Discovery & Development
Contract Research & Services Clinical Trials Contract Research Contract Services
Automation IT & Software Laboratory Instrumentation
Inward Investment Packaging Regulatory Affairs
Intelligence
Contamination Concerns
Published by Phage Consultants
White Papers
Phenom™ G2 pro
Published by Phenom World
White Papers
Internet usage of Indian General Practitioners
Published by Kinapse
White Papers
The Pulse on Recruitment--Recruiting patients on TV and radio
Published by CenterWatch
White Papers
Buy the latest industry research online today!
Nanotechnology in Drug Delivery - Technological Improvements and Novel Approaches to Fulfill High Potential
GBI Research, the leading business intelligence provider, has released its latest report, “Nanotechnology in Drug Delivery - Technological Improvements and Novel Approaches to Fulfill High Potential” that provides key data, information and analysis of the major trends and issues affecting the global nano-enabled drug delivery market. The report provides a comprehensive insight into the current and future application of nanotechnology in the drug delivery systems. It also provides an insight into the key drivers and barriers for the market growth. The report also provides a detailed analysis of the trends and its effects on the nano-enabled drug delivery market. The report also talks about the key regulations that affect the nanotechnology research and development and issues related to its use in pharmaceutical market. The report also details some case study of the latest technology being exploited in pharmaceutical industry. The report also provides detailed analysis of major deals that have happened in the nano-enabled drug delivery market landscape. At the end, the report looks into the future players. This report is built using data and information sourced from proprietary databases, primary and secondary research and in house analysis by GBI Research’s team of industry experts. The nano-enabled drug delivery market has been a high growth market and expected to grow at a faster rate in the near future. According to a study conducted by Willi Paul, and Chandra P. Sharma, the nano-enabled drug delivery market was $1.7 billion in 2009 and expected to reach over $4.8 billion in 2012. The market will witness increased competition, high investment from venture capitalist and government. The M&A and Licensing landscape will see significant changes in the coming future. This is because market is expected to become more lucrative in coming future. The major drivers for the market growth are Increasing acceptance of nano-enabled drugs, and a strong pipeline portfolio. The increasing governmental funding and R&D interest will strengthen the market in future. However, lack of consistent policy on technology transfer, poor R&D facility, and tight audit control and lack of centralized system will restrain the market growth. The nano-enabled drug delivery market has strong pipeline. The pipeline is primarily dominated by molecules in early stage of development. This suggests that the there is high level of R&D investment. This will support the future market and will fuel the licensing activity. Reports Buy online from $3500
GBI Research, the leading business intelligence provider, has released its latest report, “Nanotechnology in Drug Delivery - Technological Improvements and Novel Approaches to Fulfill High Potential” that provides key data, information and analysis of the major trends and issues affecting the global nano-enabled drug delivery market. The report provides a comprehensive insight into the current and future application of nanotechnology in the drug delivery systems. It also provides an insight into the key drivers and barriers for the market growth. The report also provides a detailed analysis of the trends and its effects on the nano-enabled drug delivery market. The report also talks about the key regulations that affect the nanotechnology research and development and issues related to its use in pharmaceutical market. The report also details some case study of the latest technology being exploited in pharmaceutical industry. The report also provides detailed analysis of major deals that have happened in the nano-enabled drug delivery market landscape. At the end, the report looks into the future players. This report is built using data and information sourced from proprietary databases, primary and secondary research and in house analysis by GBI Research’s team of industry experts. The nano-enabled drug delivery market has been a high growth market and expected to grow at a faster rate in the near future. According to a study conducted by Willi Paul, and Chandra P. Sharma, the nano-enabled drug delivery market was $1.7 billion in 2009 and expected to reach over $4.8 billion in 2012. The market will witness increased competition, high investment from venture capitalist and government. The M&A and Licensing landscape will see significant changes in the coming future. This is because market is expected to become more lucrative in coming future. The major drivers for the market growth are Increasing acceptance of nano-enabled drugs, and a strong pipeline portfolio. The increasing governmental funding and R&D interest will strengthen the market in future. However, lack of consistent policy on technology transfer, poor R&D facility, and tight audit control and lack of centralized system will restrain the market growth. The nano-enabled drug delivery market has strong pipeline. The pipeline is primarily dominated by molecules in early stage of development. This suggests that the there is high level of R&D investment. This will support the future market and will fuel the licensing activity. Reports Buy online from $3500
Comments may be moderated for spam, obscenities or defamation.